LFM-A13

Key Product Details

Product Description

LFM-A13 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Inhibits recombinant BTK with an IC₅₀ value of 2.5 μM and has no activity on other protein kinases ( including JAK1, JAK3, HCK, EGFR kinase and insulin receptor kinase) at concentrations of up to 278 μM.

Product Specifications for LFM-A13

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for LFM-A13

The following data is based on the product molecular weight 360.00.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.78 mL	13.89 mL	27.78 mL
5 mM	0.56 mL	2.78 mL	5.56 mL
10 mM	0.28 mL	1.39 mL	2.78 mL
50 mM	0.06 mL	0.28 mL	0.56 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 24 publications citing the usage of this product.

• Mahajan Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide]. J.Biol.Chem. 1999 PMID: 10092645
• Vassilev Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J.Biol.Chem. 1999 PMID: 9880544
• Crosby and Pool Interaction of Bruton's tyrosine kinase and protein kinase Cθ in platelets. J.Biol.Chem. 2002 PMID: 11788586

Product Documents for LFM-A13